Velkommen til Dansk Lungemedicinsk Selskab

Dansk Lungemedicinsk Selskab formål er at arbejde for optimal behandling, forebyggelse og forskning blandt mennesker med lungesygdomme. Dette opnås ved at sikre kvalitet i uddannelse, forskning, samarbejde og tværfaglighed.

Dansk Lungemedicinsk Selskab har repræsentanter i Danmarks Lungeforening og indgår i Dansk Selskab for Intern Medicin (DSIM) samt European Respiratory Society.

fb artDansk Lungemedicinsk Selskab har mere end 10 stående udvalg indenfor f.eks. telemedicin, retningslinjer m.m. og deltager med repræsentanter i forskellige udvalg under Sundhedsstyrelsen. Foreningen af Yngre Lungemedicinere, som repræsenterer næste generation af lungemedicinske speciallæge, er organiseret under Dansk Lungemedicinsk Selskab.

Dansk Lungemedicinsk Selskab er det faglige selskab for dig, som vil skabe bedre vilkår for vore lungepatienter nu og i fremtiden.

Næste Årsmøde: 29-30. november, 2019. Odense | Invitation | Tilmelding | Program | Dagsorden generalforsamling

Emner: Lungecancer, hoste, allergi m.m.

 

Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study

Professor: Nina Skavlan Godtfredsen 

Artikel link | DOI | PubMed | Journal: Lancet Respir Med I Dato: 2019 Okt

Kommentar til artiklen:

Indtil nu har det været formodet og vist i ældre studier, at rygeophør mindsker det accelererede lungefunktionstab ganske hurtigt efter rygestoppet. Denne artikel, som inkluderer over 25.000 deltagere fra 6 forskellige kohortestudier (generelle befolkning) i USA, viser at selv langvarig eks-rygning (> 30 år) er forbundet med et større årligt fald i FEV1 sammenlignet med aldrig rygere. Desuden viser studiet at rygere med under 10 pakkeår samt rygere med meget lavt forbrug (< 5 cig/dag) også har accelereret fald i FEV1 sammenlignet med både aldrig- og eksrygere. Sidstnævnte resultater er også vist tidligere i befolkningsundersøgelserne herhjemme. 

Abstract

Background

Former smokers now outnumber current smokers in many developed countries, and current smokers are smoking fewer cigarettes per day. Some data suggest that lung function decline normalises with smoking cessation; however, mechanistic studies suggest that lung function decline could continue. We hypothesised that former smokers and low-intensity current smokers have accelerated lung function decline compared with never-smokers, including among those without prevalent lung disease.

Methods

We used data on six US population-based cohorts included in the NHLBI Pooled Cohort Study. We restricted the sample to participants with valid spirometry at two or more exams. Two cohorts recruited younger adults (≥17 years), two recruited middle-aged and older adults (≥45 years), and two recruited only elderly adults (≥65 years) with examinations done between 1983 and 2014. FEV 1 decline in sustained former smokers and current smokers was compared to that of never-smokers by use of mixed models adjusted for sociodemographic and anthropometric factors. Differential FEV 1 decline was also evaluated according to duration of smoking cessation and cumulative (number of pack-years) and current (number of cigarettes per day) cigarette consumption.

Findings

25 352 participants (ages 17–93 years) completed 70 228 valid spirometry exams. Over a median follow-up of 7 years (IQR 3–20), FEV 1 decline at the median age (57 years) was 31·01 mL per year (95% CI 30·66–31·37) in sustained never-smokers, 34·97 mL per year (34·36–35·57) in former smokers, and 39·92 mL per year (38·92–40·92) in current smokers. With adjustment, former smokers showed an accelerated FEV 1 decline of 1·82 mL per year (95% CI 1·24–2·40) compared to never-smokers, which was approximately 20% of the effect estimate for current smokers (9·21 mL per year; 95% CI 8·35–10·08). Compared to never-smokers, accelerated FEV 1 decline was observed in former smokers for decades after smoking cessation and in current smokers with low cumulative cigarette consumption (<10 pack-years). With respect to current cigarette consumption, the effect estimate for FEV 1 decline in current smokers consuming less than five cigarettes per day (7·65 mL per year; 95% CI 6·21–9·09) was 68% of that in current smokers consuming 30 or more cigarettes per day (11·24 mL per year; 9·86–12·62), and around five times greater than in former smokers (1·57 mL per year; 1·00–2·14). Among participants without prevalent lung disease, associations were attenuated but were consistent with the main results.

Interpretation

Former smokers and low-intensity current smokers have accelerated lung function decline compared with never-smokers. These results suggest that all levels of smoking exposure are likely to be associated with lasting and progressive lung damage.